Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences adds to its board

Dr Barry Kenny and Dr Andrew Southan join the company

Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see the group strengthen the company’s focus on commercial and business development capabilities.

Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

He has held roles for Paradigm Therapeutics and Pfizer.

Dr Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017.

He has over 25 years’ experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.

Dr Keith McCullagh, non-executive chairman of Metrion Biosciences, said: “I am delighted to welcome both Barry and Andy to Metrion’s board of directors.

“Barry’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business, and Andy’s dedication to Metrion’s client service and quality of operations has been a major factor of growth of the business.”

20th March 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics